Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection

Simple item page
buir.contributor.authorYılmaz, İsmail Cem
buir.contributor.authorBülbül, Artun
buir.contributor.authorTuray, Nilsu
buir.contributor.authorYıldırım, Muzaffer
buir.contributor.authorEvcili, İrem
buir.contributor.authorGüngör, Bilgi
buir.contributor.authorSaraydar, Berfu
buir.contributor.authorBartan, Aslı Gülce
buir.contributor.authorİbibik, Bilgehan
buir.contributor.authorBildik, Tuğçe
buir.contributor.authorCeylan, Yasemin
buir.contributor.authorYıldırım, Tuğçe
buir.contributor.authorAbraş, İrem
buir.contributor.authorAykut, Gamze
buir.contributor.authorGürsel, İhsan
buir.contributor.orcidBülbül, Artun|0000-0003-1301-8368
buir.contributor.orcidTuray, Nilsu|0000-0002-6365-3469
buir.contributor.orcidAykut, Gamze|0000-0003-2184-8628
buir.contributor.orcidGürsel, İhsan|0000-0003-3761-1166
dc.citation.epage270en_US
dc.citation.issueNumber1en_US
dc.citation.spage258en_US
dc.citation.volumeNumber77en_US
dc.contributor.authorYılmaz, İsmail Cem
dc.contributor.authorİpekoğlu, E. M.
dc.contributor.authorBülbül, Artun
dc.contributor.authorTuray, Nilsu
dc.contributor.authorYıldırım, Muzaffer
dc.contributor.authorEvcili, İrem
dc.contributor.authorYılmaz, N. S.
dc.contributor.authorGüvençli, N.
dc.contributor.authorAydın, Y.
dc.contributor.authorGüngör, Bilgi
dc.contributor.authorSaraydar, Berfu
dc.contributor.authorBartan, Aslı Gülce
dc.contributor.authorİbibik, Bilgehan
dc.contributor.authorBildik, Tuğçe
dc.contributor.authorBaydemir, İ.
dc.contributor.authorŞanlı, H. A.
dc.contributor.authorKayaoğlu, B.
dc.contributor.authorCeylan, Yasemin
dc.contributor.authorYıldırım, Tuğçe
dc.contributor.authorAbraş, İrem
dc.contributor.authorAyanoğlu, C.
dc.contributor.authorCam, S. B.
dc.contributor.authorDede, E. C.
dc.contributor.authorGizer, M.
dc.contributor.authorErganis, O.
dc.contributor.authorSaraç, F.
dc.contributor.authorUzar, S.
dc.contributor.authorEnul, H.
dc.contributor.authorAdıay, C.
dc.contributor.authorAykut, Gamze
dc.contributor.authorPolat, H.
dc.contributor.authorYıldırım, İ. S.
dc.contributor.authorTekin, S.
dc.contributor.authorKörüklüoğlu, G.
dc.contributor.authorZeytin, H. E.
dc.contributor.authorKorkusuz, P.
dc.contributor.authorGürsel, İhsan
dc.contributor.authorGürsel, M.
dc.date.accessioned2022-02-15T13:41:07Z
dc.date.available2022-02-15T13:41:07Z
dc.date.issued2021-09-14
dc.departmentDepartment of Molecular Biology and Geneticsen_US
dc.description.abstractBackground Vaccines that incorporate multiple SARS-CoV-2 antigens can further broaden the breadth of virus-specific cellular and humoral immunity. This study describes the development and immunogenicity of SARS-CoV-2 VLP vaccine that incorporates the four structural proteins of SARS-CoV-2. Methods VLPs were generated in transiently transfected HEK293 cells, purified by multimodal chromatography, and characterized by tunable-resistive pulse sensing, AFM, SEM, and TEM. Immunoblotting studies verified the protein identities of VLPs. Cellular and humoral immune responses of immunized animals demonstrated the immune potency of the formulated VLP vaccine. Results Transiently transfected HEK293 cells reproducibly generated vesicular VLPs that were similar in size to and expressing all four structural proteins of SARS-CoV-2. Alum adsorbed, K3-CpG ODN-adjuvanted VLPs elicited high titer anti-S, anti-RBD, anti-N IgG, triggered multifunctional Th1-biased T-cell responses, reduced virus load, and prevented lung pathology upon live virus challenge in vaccinated animals. Conclusion These data suggest that VLPs expressing all four structural protein antigens of SARS-CoV-2 are immunogenic and can protect animals from developing COVID-19 infection following vaccination.en_US
dc.description.provenanceSubmitted by Samet Emre (samet.emre@bilkent.edu.tr) on 2022-02-15T13:41:07Z No. of bitstreams: 1 Development_and_preclinical_evaluation_of_virus-like_particle_vaccine_against_COVID-19_infection.pdf: 2111935 bytes, checksum: 90f65ab96e5d3c263c5a281b4cb1aaf3 (MD5)en
dc.description.provenanceMade available in DSpace on 2022-02-15T13:41:07Z (GMT). No. of bitstreams: 1 Development_and_preclinical_evaluation_of_virus-like_particle_vaccine_against_COVID-19_infection.pdf: 2111935 bytes, checksum: 90f65ab96e5d3c263c5a281b4cb1aaf3 (MD5) Previous issue date: 2021-09-14en
dc.embargo.release2022-09-14
dc.identifier.doi10.1111/all.15091en_US
dc.identifier.eissn1398-9995
dc.identifier.issn0105-4538
dc.identifier.urihttp://hdl.handle.net/11693/77399
dc.language.isoEnglishen_US
dc.publisherWiley-Blackwell Publishing Ltd.en_US
dc.relation.isversionofhttps://doi.org/10.1111/all.15091en_US
dc.source.titleAllergyen_US
dc.subjectCovid-19en_US
dc.subjectCpG ODN Adjuvanten_US
dc.subjectSARS-CoV-2en_US
dc.subjectVaccineen_US
dc.subjectVirus-like particleen_US
dc.titleDevelopment and preclinical evaluation of virus-like particle vaccine against COVID-19 infectionen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Development_and_preclinical_evaluation_of_virus-like_particle_vaccine_against_COVID-19_infection.pdf
Size:
2.01 MB
Format:
Adobe Portable Document Format
Description:
Download

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.69 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Scholarly Publications - Molecular Biology and Genetics